This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Epigenetic Therapies And Technologies: World Market Prospects 2013-2023

What prospects for leading regions and countries?

Developments worldwide will influence the market from 2013. There are many opportunities for healthcare companies large and small.

You discover individual revenue forecasts to 2023 for eight national markets and two regional blocks. Find relevant overall sales:• US• Canada• Japan• Germany, France, UK, Italy and Spain (EU5 countries)• Europe• Brazil, Russia, India and China (BRIC nations, grouped analysis).

You find potential. High sales growth will occur in established pharma markets and in developing countries, our analyses show. In particular, drug launches will change the commercial landscape to 2023.

Research and development - see trends and possibilities

What's happening in epigenetic R&D? You see trends and outlooks there:

• HDAC inhibitors

• DNMT inhibitors

• Treatments targeting other enzymes

• MiRNA therapy

• Diagnostics pipeline.

Our study also discusses these technologies, among others:• New drug targets• Biomarkers• Bioinformatics• Next generation sequencing.

Discover progress. You assess innovations affecting the industry's future - hear about developments and find their significance. Our work explains, exploring many issues.

What affects the application of epigenetics?

Our report discusses issues and events affecting that science, industry and market from 2013 onwards:

• Cancer research and treatment

• DNA hypomethylation in autoimmune diseases

• Neurodegenerative diseases

• Neurological disorders

• Understanding of epigenetic markers and mechanisms.

Also, you find coverage of these aspects of the field:• Genomics, proteomics and metabolomics• Translational research• Licensing, outsourcing and academic collaborations• Developments with stem cells• Orphan indications and patient subpopulations• Companion diagnostics and stratified medicine.

See what the future holds. You investigate technological, commercial, economic and political matters, with emphasis on companies, competition and business outlooks.

2 of 12

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,825.82 +13.63 0.08%
S&P 500 2,089.14 +2.55 0.12%
NASDAQ 5,102.8080 +0.33 0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs